HRP20201761T1 - Prilagođeni liposomi za tretman bakterijskih infekcija - Google Patents
Prilagođeni liposomi za tretman bakterijskih infekcija Download PDFInfo
- Publication number
- HRP20201761T1 HRP20201761T1 HRP20201761TT HRP20201761T HRP20201761T1 HR P20201761 T1 HRP20201761 T1 HR P20201761T1 HR P20201761T T HRP20201761T T HR P20201761TT HR P20201761 T HRP20201761 T HR P20201761T HR P20201761 T1 HRP20201761 T1 HR P20201761T1
- Authority
- HR
- Croatia
- Prior art keywords
- empty liposomes
- sphingomyelin
- cholesterol
- phosphatidylcholine
- liposomes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12171924 | 2012-06-14 | ||
| EP13153039 | 2013-01-29 | ||
| EP13732388.7A EP2861214B1 (en) | 2012-06-14 | 2013-06-13 | Tailored liposomes for the treatment of bacterial infections |
| PCT/EP2013/062207 WO2013186286A1 (en) | 2012-06-14 | 2013-06-13 | Tailored liposomes for the treatment of bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201761T1 true HRP20201761T1 (hr) | 2020-12-25 |
Family
ID=48703423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201761TT HRP20201761T1 (hr) | 2012-06-14 | 2013-06-13 | Prilagođeni liposomi za tretman bakterijskih infekcija |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10744089B2 (enExample) |
| EP (2) | EP2861214B1 (enExample) |
| JP (2) | JP6382801B2 (enExample) |
| CN (2) | CN104602672B (enExample) |
| AU (2) | AU2013276565B2 (enExample) |
| BR (1) | BR112014031278B1 (enExample) |
| CA (1) | CA2875470C (enExample) |
| CY (1) | CY1123337T1 (enExample) |
| DK (1) | DK2861214T3 (enExample) |
| ES (1) | ES2821502T3 (enExample) |
| HR (1) | HRP20201761T1 (enExample) |
| HU (1) | HUE051761T2 (enExample) |
| LT (1) | LT2861214T (enExample) |
| PL (1) | PL2861214T3 (enExample) |
| RS (1) | RS60951B1 (enExample) |
| RU (1) | RU2672106C2 (enExample) |
| SI (1) | SI2861214T1 (enExample) |
| SM (1) | SMT202000584T1 (enExample) |
| WO (1) | WO2013186286A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2861214B1 (en) | 2012-06-14 | 2020-08-05 | Universität Bern | Tailored liposomes for the treatment of bacterial infections |
| WO2015084677A1 (en) | 2013-12-02 | 2015-06-11 | Arytha Biosciences, Llc | Toxoid preparation and uses thereof |
| US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
| CA3009119A1 (en) | 2015-12-28 | 2017-07-06 | Mb Biotech Ltd. | Liposomes for treatment of an autoimmune disease |
| WO2017177073A1 (en) * | 2016-04-07 | 2017-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use |
| DK3471732T3 (da) | 2016-06-16 | 2020-08-17 | Combioxin Sa | Liposomer til behandling af virusinfektioner |
| ES3060425T3 (en) | 2017-03-02 | 2026-03-26 | Combioxin Sa | Liposomes for inhibiting biofilm formation |
| US11344497B1 (en) * | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| KR102915698B1 (ko) * | 2018-04-17 | 2026-01-28 | 콤비옥신 에스에이 | 폐렴의 치료 |
| PT3781210T (pt) * | 2018-04-20 | 2024-10-02 | Combioxin Sa | Tratamento da hipotensão com sépsis ou choque séptico |
| CN111214439B (zh) * | 2018-11-23 | 2023-02-10 | 复旦大学 | 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途 |
| EP4093458A4 (en) | 2020-01-20 | 2024-01-17 | Arytha Biosciences LLC | Devices containing cellular membrane and uses thereof |
| JP2023536833A (ja) * | 2020-07-31 | 2023-08-30 | サインパス ファルマ，インク． | サイトカイン放出及びサイトカインストームの抑制 |
| CN115054577B (zh) * | 2022-05-17 | 2024-06-21 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 纳米解毒剂及其在中和mrsa穿孔毒素的应用 |
| WO2026099472A1 (en) | 2024-11-08 | 2026-05-15 | Universität Bern | Liposomal compositions for treatment of inflammation |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3641247A (en) | 1970-12-14 | 1972-02-08 | Stanley Drug Products Inc | Methods of treating bacterial infections |
| WO1991004019A1 (en) * | 1989-09-12 | 1991-04-04 | The Regents Of The University Of California | Therapeutic peptides and proteins |
| NL9000207A (enExample) * | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
| WO1993004672A1 (en) * | 1991-09-11 | 1993-03-18 | Pitman-Moore, Inc. | Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides |
| US5741516A (en) * | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| US8110217B2 (en) * | 2001-08-13 | 2012-02-07 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
| US20050118250A1 (en) * | 2001-11-13 | 2005-06-02 | Paul Tardi | Lipid carrier compositions with enhanced blood stability |
| CA2368656A1 (en) * | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| JP4187249B2 (ja) | 2002-03-08 | 2008-11-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プレシナプス蛋白ｐ１２０ |
| AU2003265241A1 (en) * | 2002-05-23 | 2003-12-12 | Activbiotics, Inc. | Methods of treating bacterial infections and diseases associated therewith |
| AU2003298738A1 (en) * | 2002-11-26 | 2004-06-18 | Su-Ming Chiang | Liposomal formulations |
| WO2004087097A2 (en) * | 2003-03-31 | 2004-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer |
| KR101462825B1 (ko) | 2004-05-03 | 2014-11-21 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
| AU2005304914B2 (en) * | 2004-11-05 | 2012-02-16 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal camptothecin formulations |
| US20090186073A1 (en) | 2005-08-11 | 2009-07-23 | National Institute Of Advanced Industrial Science And Technology | Design of Delivery Vehicle Based On Rolling Model |
| CN1939340A (zh) * | 2005-09-29 | 2007-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 脂质体制剂 |
| US20080131497A1 (en) | 2006-09-28 | 2008-06-05 | Perkins Walter R | Formulations of DNase and Methods of Use Thereof |
| US9637515B2 (en) * | 2006-11-06 | 2017-05-02 | Jina Pharmaceuticals, Inc. | Guggulphospholipid methods and compositions |
| CN1994279A (zh) * | 2006-12-31 | 2007-07-11 | 西安力邦医药科技有限责任公司 | 注射用盐酸伊立替康脂质体的制备方法 |
| US8906855B2 (en) | 2007-12-22 | 2014-12-09 | Vivacelle Bio, Inc. | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
| CN101623262B (zh) * | 2009-08-24 | 2011-02-02 | 海南美大制药有限公司 | 一种五水头孢唑啉钠前体脂质体制剂 |
| WO2011160110A1 (en) * | 2010-06-19 | 2011-12-22 | Western University Of Health Sciences | Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics |
| WO2012021107A2 (en) * | 2010-08-12 | 2012-02-16 | Nanyang Technological University | A liposomal formulation for ocular drug delivery |
| CN102327220B (zh) * | 2011-07-14 | 2012-09-26 | 海南灵康制药有限公司 | 一种氯雷他定脂质体固体制剂 |
| EP2861214B1 (en) | 2012-06-14 | 2020-08-05 | Universität Bern | Tailored liposomes for the treatment of bacterial infections |
| US10716756B2 (en) | 2016-06-20 | 2020-07-21 | Vivacelle Bio, Inc. | Compositions and methods for reducing reperfusion injury |
| ES3060425T3 (en) | 2017-03-02 | 2026-03-26 | Combioxin Sa | Liposomes for inhibiting biofilm formation |
| KR102915698B1 (ko) | 2018-04-17 | 2026-01-28 | 콤비옥신 에스에이 | 폐렴의 치료 |
-
2013
- 2013-06-13 EP EP13732388.7A patent/EP2861214B1/en active Active
- 2013-06-13 ES ES13732388T patent/ES2821502T3/es active Active
- 2013-06-13 HU HUE13732388A patent/HUE051761T2/hu unknown
- 2013-06-13 SI SI201331806T patent/SI2861214T1/sl unknown
- 2013-06-13 JP JP2015516609A patent/JP6382801B2/ja active Active
- 2013-06-13 CA CA2875470A patent/CA2875470C/en active Active
- 2013-06-13 US US14/404,985 patent/US10744089B2/en active Active
- 2013-06-13 PL PL13732388T patent/PL2861214T3/pl unknown
- 2013-06-13 DK DK13732388.7T patent/DK2861214T3/da active
- 2013-06-13 CN CN201380031384.7A patent/CN104602672B/zh active Active
- 2013-06-13 EP EP20189368.2A patent/EP3782606A1/en active Pending
- 2013-06-13 RU RU2014148284A patent/RU2672106C2/ru active
- 2013-06-13 RS RS20201252A patent/RS60951B1/sr unknown
- 2013-06-13 BR BR112014031278-8A patent/BR112014031278B1/pt active IP Right Grant
- 2013-06-13 WO PCT/EP2013/062207 patent/WO2013186286A1/en not_active Ceased
- 2013-06-13 SM SM20200584T patent/SMT202000584T1/it unknown
- 2013-06-13 HR HRP20201761TT patent/HRP20201761T1/hr unknown
- 2013-06-13 LT LTEP13732388.7T patent/LT2861214T/lt unknown
- 2013-06-13 CN CN201811433069.8A patent/CN109549925B/zh active Active
- 2013-06-13 AU AU2013276565A patent/AU2013276565B2/en active Active
-
2018
- 2018-08-02 JP JP2018145681A patent/JP6656321B2/ja active Active
-
2019
- 2019-03-14 AU AU2019201776A patent/AU2019201776B2/en active Active
-
2020
- 2020-07-09 US US16/924,539 patent/US20200345639A1/en not_active Abandoned
- 2020-09-16 CY CY20201100878T patent/CY1123337T1/el unknown
-
2021
- 2021-11-30 US US17/537,862 patent/US20220087934A1/en not_active Abandoned
-
2022
- 2022-09-30 US US17/957,402 patent/US12599558B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519383A5 (enExample) | ||
| RU2014148284A (ru) | Специально разработанные липосомы для лечения бактериальных инфекций | |
| JP2018184470A5 (enExample) | ||
| US8871811B2 (en) | Permeation enhancers for topical formulations | |
| CA2764227C (en) | Formulations for the treatment of deep tissue pain | |
| HRP20191805T1 (hr) | Postupci za liječenje netuberkuloznih mikobakterijskih infekcija pluća | |
| BR112015002584A8 (pt) | uso de lipossoma e composição farmacêutica | |
| JP2016040277A (ja) | 小胞状の製剤 | |
| KR850002401A (ko) | 독성을 감소시키는 약제의 제조방법 | |
| JP2021091730A (ja) | 多相組成物 | |
| MX2014012198A (es) | Formulaciones vesiculares para su uso en el tratamiento del dolor o movilidad reducida de una articulacion. | |
| UA111147C2 (uk) | Способи та композиції для лікування або профілактики зовнішнього отиту | |
| JP6374558B2 (ja) | 皮膚科障害または皮膚科疾患を処置するための新規製剤および方法 | |
| US20120201871A1 (en) | Permeation enhancers with liposomes for topical formulations | |
| JP2015516453A (ja) | ベシクル製剤の使用および方法 | |
| US20150132349A1 (en) | Vesicular Formulations, Kits and Uses | |
| HK40058716A (en) | Multiphasic compositions |